KROS (Keros Therapeutics) Other Current Receivables: $2.56 Mil (As of Mar. 2026)


KROS Keros Therapeutics Inc KROS
30 GF Score
Price $11.67
! 2 Warning Signs
View Full Analysis

What is Keros Therapeutics Other Current Receivables?

Keros Therapeutics KROS +0.21% 30 Other Current Receivables is $2.56 Mil as of Mar. 2026. GuruFocus rates KROS with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Keros Therapeutics's Other Current Receivables for the quarter that ended in Mar. 2026 was $2.56 Mil.

Keros Therapeutics's quarterly Other Current Receivables increased from Sep. 2025 ($2.07 Mil) to Dec. 2025 ($2.81 Mil) but then stayed the same from Dec. 2025 ($2.81 Mil) to Mar. 2026 ($2.56 Mil).

Keros Therapeutics's annual Other Current Receivables increased from Dec. 2023 ($0.95 Mil) to Dec. 2024 ($1.71 Mil) and increased from Dec. 2024 ($1.71 Mil) to Dec. 2025 ($2.81 Mil).

Keros Therapeutics Other Current Receivables Related Terms

Keros Therapeutics Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Keros Therapeutics's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Keros Therapeutics Other Current Receivables Chart

Keros Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial 0.20 0.84 0.95 1.71 2.81

Keros Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.08 1.92 2.07 2.81 2.56
KROS
30GF Score
Keros Therapeutics Inc KROS
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Keros Therapeutics Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of $2.56 Mil mean?
Keros Therapeutics (KROS) has a Other Current Receivables of $2.56 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Keros Therapeutics and its competitors.
Is Keros Therapeutics' Other Current Receivables too high?
Keros Therapeutics' current Other Current Receivables is $2.56 Mil. Overall, Keros Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Keros Therapeutics' Other Current Receivables compare to CDXS and CAMP?
Keros Therapeutics' Other Current Receivables of $2.56 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Keros Therapeutics and its competitors. Keros Therapeutics's current Other Current Receivables is $2.56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Keros Therapeutics stock overvalued right now?
Keros Therapeutics (KROS) has a current Other Current Receivables of $2.56 Mil. The current Other Current Receivables is $2.56 Mil. Keros Therapeutics' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Keros Therapeutics (KROS), the current Other Current Receivables is $2.56 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Keros Therapeutics Business Description

Address 1050 Waltham Street, Suite 302, Lexington, MA, USA, 02421
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
30GF Score

Get the complete analysis for KROS

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.67
Price